Recurrent Nasal Polyps After One Surgery: A Biologic Trial or a Second Trip to the Operating Room
A second recurrence after a surgery that already proved capable of clearing the disease once — and didn't hold.
Marcus F., a 58-year-old retired firefighter, underwent functional endoscopic sinus surgery for bilateral nasal polyps three years ago with genuine relief for about eighteen months before his congestion, anosmia, and facial pressure crept back. Today his endoscopy confirms recurrent polyps obstructing both middle meatuses, his SNOT-22 score has climbed back to 68 from a post-surgical low of 12, and he has lost his sense of smell entirely again — something he says affects his enjoyment of cooking, a retirement hobby he took up specifically because he finally had time for it. He has mild persistent asthma, well-controlled on a low-dose inhaled corticosteroid, and a blood eosinophil count today of 420 cells/µL.
His recurrence is the actual clinical fact driving today's conversation, more than the polyps' current size: surgery already proved capable of clearing his sinuses once, and the disease came back anyway, which argues that anatomic correction alone was never addressing whatever is regrowing the tissue. Dupilumab's SINUS-24 and SINUS-52 trials enrolled adults with recurrent, symptomatic CRSwNP despite prior surgery, many with comorbid asthma and elevated blood eosinophils — a population his own numbers sit squarely inside, not at the edge of. Whether that trial-population match should be the deciding factor over a second, more anatomically direct surgical correction is the real fork the group is facing, not a referendum on biologics versus surgery in the abstract.
He has no other chronic medical conditions besides his asthma and quit smoking eleven years ago after a twenty-year history, a detail he volunteers readily since he knows it's relevant to sinus disease generally, even though his current recurrence pattern maps far more closely onto eosinophilic, type 2-driven CRSwNP than onto smoking-related mucosal disease. His asthma control has actually been excellent throughout the three years since his surgery, with no exacerbations and stable spirometry — which makes his sinus recurrence a relatively isolated problem within an otherwise well-managed set of airway conditions, rather than part of a broader pattern of poor control across both compartments.
A recurrence that already answered part of the question
His own history already ran the experiment we'd otherwise be debating in the abstract: surgery cleared his sinuses once, and the disease came back within eighteen months anyway. That means whatever is driving polyp regrowth was never addressed by anatomic correction alone — a biologic targeting his confirmed type 2 signature and elevated eosinophil count goes after the actual process, not the anatomy downstream of it.
I don't disagree that recurrence is meaningful evidence. What I'd weigh against it is that revision surgery has a real, well-characterized track record and gives faster, more predictable relief than waiting months to see a biologic's full effect — and a biologic is a long-term commitment with real cost and administration burden he'd be taking on indefinitely.
Reserving biologics for patients who fail an adequately performed revision, rather than substituting for one, is still a defensible default — his recurrence doesn't automatically mean surgery failed him, only that eighteen months wasn't permanent.
The actual decisive fact isn't a general preference for medical over surgical management — it's whether he specifically matches the population the biologic trials studied. SINUS-24 and SINUS-52 enrolled adults with recurrent CRSwNP despite prior surgery, many with comorbid asthma and elevated eosinophils. His asthma, his eosinophil count, and his surgical history all sit inside that population, not at its edge.
That's a more specific basis for choosing the biologic than either "surgery already failed once" or "surgery is more predictable" alone — it's a checkable match to the actual evidence, not a generic philosophy about which modality to prefer.
Agreed: start dupilumab and hold revision surgery in reserve, on the strength of his direct match to the trial-enrolled population rather than a general medical-versus-surgical preference.
Not agreed: how long a biologic trial should run before revision surgery re-enters the conversation if improvement is partial. The otolaryngologist wants a defined, relatively short window given how disruptive his anosmia is to his daily life; the allergist would give the biologic a longer run given how gradually type 2 inflammatory disease can respond, especially in tissue this chronically remodeled.